Target will report earnings before the bell on Wednesday. The discounter's annual sales have been stagnant for roughly four years and it forecast a sales decline for this fiscal year.
Target's recent Q2 report was disastrous, leading to a sharp decline in the stock. Despite the negative results, there is a basic bullish scenario for Target at long odds. Investing in Target now is a long-shot bet, similar to betting against the house.
Zihahn Ma, Bernstein, joins 'Closing Bell Overtime' to talk what to expect from Target quarterly results.
Target gears up for Q2 earnings with falling sales and profit estimates, as investors weigh digital gains against weak store traffic.
NBIS boosts ARR outlook to $1.1 billion as it scales data-center capacity. It is targeting 1 GW by 2026 to capture AI-infrastructure demand.
Ultimately, the decision of which retail stock may be the better investment comes down to whether investors want to bet on value for the long-term or growth and defensive safety at the moment.
I reiterate my buy rating on Merck, citing its attractive valuation and improving technicals despite sector headwinds. Merck's recent earnings beat was driven by strong oncology and cardiovascular portfolios, offsetting Gardasil weakness and Keytruda patent concerns. The stock offers a solid 4% dividend yield, low PEG ratio, and consistent growth, making it appealing for income and value investors.
Ulta Beauty and Target just announced they won't renew their five-year partnership after reaching 600 Ulta-Target shop-in-shops, falling short of their original goal of 800 locations. With the partnership ending in August 2026, Target's got a year to prepare to dismantle the Ulta in-store concessions, which can span up to 1,000 square feet, and repurpose the space.
BofA analysts downgrade Target, saying the retailer is “underperforming peers on sales, digital growth, and investments.”
Can Target turn it around?
Target Corp (NYSE:TGT) shares fell around 1.6% Friday after Bank of America downgraded the retailer to “Underperform” from “Neutral,” citing what it described as deteriorating long-term prospects. BofA lowered its price target to $93 from $105, noting that Target is lagging behind competitors on sales, digital growth, and strategic investments.
Beyond analysts' top-and-bottom-line estimates for Target (TGT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended July 2025.